New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 20, 2014
09:15 EDTLIVE, DNDN, GPK, TJX, ICPT, CAB, MRK, IRDM, NVS, CCL, ARX, ODP, DKS, ECYT, CLVS, OPHT, ACXM, URBN, SPLSOn The Fly: Pre-market Movers
HIGHER: Aeroflex (ARX), up 25% after agreeing to be acquired by Cobham for about $1.46B... Clovis (CLVS), up 6.6% after receiving breakthrough therapy designation for CO-1686... Ophthotech (OPHT), up 17.6% after entering into an ex-U.S. licensing, commercialization agreement with Novartis (NVS) for Fovista... Dendreon (DNDN), up 9% after announcing presentation of PROVENGE ProACT, IMPACT studies data... Iridium (IRDM), up 5% after upgraded at Raymond James... Acxiom (ACXM), up 3% after upgraded at Wells Fargo... Carnival (CCL), up 2% following upgrade at Morgan Stanley. DOWN AFTER EARNINGS: Dick's Sporting (DKS), down 15%. Peer Cabelas (CAB) also down 2% after Dick's report... Staples (SPLS), down 10%. Peer Office Depot (ODP) also down 2.6% after Staples' report... Urban Outfitters (URBN), down 4%... TJX (TJX), down 4.7%. ALSO LOWER: Intercept (ICPT), down 5.8% after The Street reported that the company knew of abnormal cholesterol levels in patients taking its liver disease drug obeticholic acid... Graphic Packaging (GPK), down 3% after offering 43.65M shares of common stock for holders... LiveDeal (LIVE), down 15% after entering 10M share common stock distribution agreement... Endocyte (ECYT), down 5% after company and partner Merck (MRK) withdraw CMA for vintafolide in Europe.... Molycorp (MCP), down 2.5% after downgraded at Morgan Stanley.
News For DKS;CAB;SPLS;ODP;ICPT;URBN;ARX;TJX;ACXM;CCL;GPK;OPHT;NVS;DNDN;CLVS;IRDM;LIVE;ECYT;MRK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
June 24, 2015
08:20 EDTCCLCarnival investments bode well for longer-term trends, says Susquehanna
Susquehanna said Carnival reported solid Q2 results, citing strong demand and moderate supply growth through 2022. The firm expects demand to stay strong for the next few quarters and for the company's strategic investments to pay off in 2016. Susquehanna reiterated its Positive rating and $56 price target on Carnival shares.
07:12 EDTODP, SPLSStaples deal unlikely after Sysco-US Foods merger blocked, NY Post reports
Subscribe for More Information
June 23, 2015
10:44 EDTCCLCarnival says it is watching MERS situation closely
The company said it modified some ship itineraries due to the MERS outbreak. The modifications were made up on request.
10:18 EDTCCLCarnival sees $27M in restructuring expenses in 2015
Subscribe for More Information
10:14 EDTCCLCarnival 'focused' on double digit return on invested capital
Subscribe for More Information
10:10 EDTCCLCarnival says China growth prospects strong, to limit capacity elsewhere
Subscribe for More Information
09:21 EDTCCLCarnival reports Q2 net revenue yields up 4.1%
Subscribe for More Information
09:20 EDTCCLCarnival sees Q3 EPS $1.56-$1.60, consensus $1.70
Subscribe for More Information
09:19 EDTCCLCarnival raises FY15 non-GAAP EPS to $2.35-$2.50 from $2.30-$2.50
FY15 EPS consensus of $2.50. Backs FY15 net revenue yields to be up 3%-4%. Expects FY15 net cruise costs excluding fuel per ALBD to be up 3%, slightly higher than had been anticipated in March guidance due to increased investment in advertising.
09:17 EDTCCLCarnival says fleetwide booking volumes running ahead of last year
Subscribe for More Information
09:17 EDTCCLCarnival reports Q2 non-GAAP EPS 25c, consensus 16c
Subscribe for More Information
08:32 EDTLIVELiveDeal identifies first target for acquisition strategy
Subscribe for More Information
June 22, 2015
15:00 EDTCCLNotable companies reporting before tomorrow's open
Subscribe for More Information
14:36 EDTCCLCarnival technical comments ahead of earnings
Ahead of earnings the stock is ticking near its 52-week high which is at $50.65. This follows a recent breakout in price which cleared the prior high at $49.21. If the news is bullish, the breakout is likely to gain momentum. Additional upside levels to watch as potential upside objectives would be at $52.10 and $54.73. If the news is bearish, the following support levels could become downside objectives: $47.39, $46.74 which is the 50-day moving average, and $45.51.
10:00 EDTCABOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Akebia (AKBA) initiated with an Outperform at JMP Securities... Barracuda Networks (CUDA) initiated with a Buy at Summit Research... BioLineRx (BLRX) initiated with an Outperform at JMP Securities... Cabela's (CAB) initiated with an Outperform at Barrington... Chemours (CC) initiated with a Buy at Jefferies... Communications Sales & Leasing (CSAL) initiated with an Overweight at JPMorgan... E.W. Scripps (SSP) initiated with a Hold at Evercore ISI... EQT Corporation (EQT) reinstated with an Overweight at Barclays... EQT GP (EQGP) initiated with an Outperform at Credit Suisse... EQT Midstream Partners (EQM) initiated with a Buy at Deutsche Bank... Eagle Pharmaceuticals (EGRX) initiated with an Outperform at RBC Capital... Energen (EGN) initiated with a Buy at KLR Group... Ignyta (RXDX) initiated with an Overweight at Piper Jaffray... International Game (IGT) initiated with a Buy at BofA/Merrill... Leju (LEJU) initiated with an Overweight at Barclays... Micron (MU) initiated with an Outperform at Cowen... People's Utah Bancorp (PUB) initiated with a Buy at DA Davidson... SouFun (SFUN) initiated with an Overweight at Barclays... Turquoise Hill (TRQ) initiated with an Outperform at BMO Capital.
10:00 EDTCCLOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:17 EDTCABCabela's initiated with an Outperform at Barrington
Subscribe for More Information
08:17 EDTCCLCarnival volatility flat into Q2 and booking outlook
Subscribe for More Information
08:03 EDTCLVSClovis names Dr. Lindsey Rolfe as Chief Medical Officer
Clovis Oncology announced that Dr. Lindsey Rolfe, BSc, MB ChB, MRCP, FFPM, has been named Chief Medical Officer and EVP of Clinical and Preclinical Development and Pharmacovigilance, to become effective in early August. Dr. Rolfe succeeds Dr. Andrew Allen, who will be stepping down from his role at Clovis at that time to create a new immuno-oncology focused biotechnology company and serve as its CEO. Dr. Rolfe joined Clovis in early 2010 and oversees rociletinib and rucaparib development in her current role as SVP of Clinical Development. As Chief Medical Officer at Clovis, Dr. Rolfe will be responsible for clinical development, preclinical development, clinical operations and pharmacovigilance and will also serve on the company’s executive committee.
07:08 EDTCCLCarnival upgraded to Buy from Hold at Deutsche Bank
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use